Quinolones as serine protease inhibitors

Details Quinolones as serine protease inhibitors Quinolones as serine protease inhibitors

2005-02-15

2005-02-15

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S252100, C514S241000, C514S256000, C546S157000, C546S158000, C544S180000, C544S238000, C544S242000, C544S336000

Reexamination Certificate

active

06855726

ABSTRACT:
The invention discloses quinolinones which display inhibitory effects on serine proteases such as factor Xa, thrombin and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs, and methods of using them a therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

REFERENCES:
patent: 3330823 (1967-07-01), Bernstein et al.
patent: 3551413 (1970-12-01), Krapcho et al.
patent: 4329347 (1982-05-01), Muller et al.
patent: 4927824 (1990-05-01), Adler et al.
patent: 25 59 509 (1976-12-01), None
patent: 197 18 181 (1998-11-01), None
patent: 0 024 638 (1980-08-01), None
patent: EP 0 797 376 (1997-09-01), None
patent: 2 439 196 (1980-05-01), None
patent: 1305278 (1970-03-01), None
patent: 50 142576 (1975-11-01), None
patent: 56-49359 (1981-01-01), None
patent: 56-125388 (1981-01-01), None
patent: WO 9707116 (1996-07-01), None
patent: WO 97 12869 (1997-04-01), None
“Chemical Abstracts Acession No. 56:12890 HCA”.
“Chemical Abstracts Acession No. 62:74780 HCA”.
“Chemical Abstracts Acession No. 51:25546 HCA”.
“Chemical Abstracts Acession No. 62:74780 HCA”.
“Chemical Abstracts Acession No. 51:81474 HCA”.
“Chemical Abstracts Acession No. 52:92876 HCA”.
“Chemical Abstracts Acession No. 123:198641 HCA”.
“Chemical Abstracts Acession No. 65:38425 HCA”.
“Chemical Abstracts Acession No. 65:38425 HCA”.
“Chemical Abstracts Acession No. 66:70538 HCA”.
“Chemical Abstracts Acession No. 74:140019 HCA”.
“Chemical Abstracts Acession No. 52:28698 HCA”.
“Chemical Abstracts Acession No. 82:81689 HCA”.
“Chemical Abstracts Acession NO. 82:81689 HCA”.
“Chemical Abstracts Acession No. 51:81474 HCA”.
“Chemical Abstracts Acession No. 84:17099 HCA”.
Lynch, J. Jr., et al., “Primary Prevention of Coronary Arterial Thrombosis with the Factor Xa Inhibitor rTAP in a Canine Electrolytic Injury Model”,Thromb. Haemostasis, 1995, vol. 74, No. 2, pp 640-645.
Schaffer, L., et al., “Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide”, Circulation, vol. 84, No. 4, 1991, pp 1741-1748.
Fioravanti, C., et al., “Antithrombotic Activity of Recombinant Tick Anticoagulant Peptide and Heparin in a Rabbit Model of Venous Thrombosis”,Thromb. Res.,1993, vol. 71, pp 317-324.
Wong, P., et al., “Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis”, Thromb. Res., 1996, vol. 83, No. 2, pp 117-126.
Edmunds, J., et al., “Chapter 6. Thrombin and Factor Xa Inhibition”, Annual Reports of Medicinal Chemistry, 1996, pp 51-60.
Kunitada, S., et al., “Factor Xa Inhibitors”, Curr. Pharm. Des., 1996, vol. 2, pp 531-542.
Van den Bogaert, J., et al., “Eletrophotographic Process Utilizing a Fluorescent Recording Material”, Res. Discl., 1992, vol. 340, pp 607-608.
Qar, J., et al., “A Novel High Affinity Class of Ca2+ Channel Blockers”, Mol. Pharmacol., 1988, vol. 33, pp 363-369.
Petyuin, P., “Substitution of the Saturated Carbon Atom During the Acidochrome Condensation of Arylides of Diarylglycoloc Acids”, Ukr. Khim. Zh., 1971, vol. 37, No. 1, pp 44-46.
Timari, G. et al., “A Convenient Synthesis of Two New Indoloquinoline Alkaloids”, Synlett, 1997, vol. 9, pp 1067-1067.
Lopez-Alvarado, P. et al., “1,2-Dihydroquinolin-2-one(carbostyril) Anions as Bidentate Nucleophiles in their Reactions with Aryllead Triacetates: synthesis of 1-aryl-and 3-aryl-tetrahydroquinoline-2,5,8-triones” J. Chem Soc. Perkin Trans. 1, 1997, vol.3, pp 229-233.
Chemical Abstract No. XP-002102648.
Chemical Abstract No. XP-002102649.

Affiliated with

Also associated with

Rating

Quinolones as serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinolones as serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolones as serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3472266